A public health expert acknowledged Japan’s success in reducing smoking rate by nearly a third in a span of just three to four years following the introduction of non-combustible alternatives to cigarettes in 2014.
Dr. Kumamaru Hiroya, vice director of the AOI Universal Hospital in Kawasaki, said cigarettes smoking in Japan declined 30 percent with the introduction of heated tobacco products, something that nicotine replacement therapy failed to accomplish.
He said the launching of HTPs like IQOS from Philip Morris International in 2014, following a market test in 2013, led to a substantial decrease in smoking rate over the next three to four years. Japan is now the world’s largest HTP market.
“In conclusion, after nicotine replacement therapy direction has been tried, they were not really a big success. However, ever since 2014, three heated tobacco products have been launched officially nationwide in Japan and these have been penetrating 25 percent [of total smoking population], and this product has been successful to reduce cigarette smoking in Japan so far by 30 percent in three to four years,” Hiroya, a preventive physician specializing in smoking cessation, said during a webinar organized by business consulting firm Frost & Sullivan on December 7, 2020.
HTPs are non-combustible alternatives to cigarettes that closely mimic the rituals of smoking minus the combustion process. These electronic devices heat, instead of burn, specially-designed tobacco units to release flavorful nicotine-containing tobacco vapor. Results of scientific studies show that tar and carcinogens found in tobacco smoke, cause the death and disease associated with smoking, and not nicotine.
The US Food and Drug Administration authorized the marketing of IQOS as a modified risk tobacco product on July 7, 2020.
The FDA’s action authorizes the marketing of IQOS in the US with the information that the IQOS system heats tobacco but does not burn it and scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces the body’s exposure to harmful or potentially harmful chemicals.
The webinar titled “Tobacco Harm Reduction and Novel Nicotine and Tobacco Products-Evidence from the Japanese Market” focused on the experience of the Japanese market following the launch of novel nicotine and tobacco products, specifically HTPs in Japan since 2014. The event was moderated by Yvonne Lucas of Frost & Sullivan.
Hiroya said HTP users accounted for about 30 percent among Japanese male smokers and 25 percent among female smokers. He said dual use of cigarettes and HTPs remained low at 6.9 percent among male smokers and 4.8 percent among female smokers.
A study by Tottori University Medical School funded by Ministry of Health and Welfare also showed that the initiation to HTP use among 60,000 Japanese junior high school students was very low at just 0.1 percent belying fears of youth uptake.
Mark Dougan, director of transformational health at Frost & Sullivan, said the case of Japan, being the world’s largest market of HTPs, deserves to be studied because of the significant reduction in smoking rate in the country.
“The reason we’re focusing on the Japanese market is because NNTPs have been commercially available in Japan since 2014. It’s by far the world’s largest market, and they put it to be commercially available now for seven years,” he said.
Over the past 15 years, a range of NNTPs have emerged with e-cigarettes first commercially introduced in 2004 and the current generation of HTPs in 2014.
Dougan said HTPs are based on the principle of eliminating combustion by heating tobacco at about 350 degrees Centigrade or less instead of burning.
“While these products are clearly not risk-free, they do have the potential to serve as a complementary strategy to existing smoking-related interventions” for smokers who are otherwise unable or unwilling to quit cigarettes,” said Dougan.
Globally, smoking remains the leading preventable cause of premature mortality, with more than 7 million people dying of smoking-related diseases each year. Dougan said the number of tobacco users worldwide declined only marginally from about 1.4 billion in 2000 to 1.34 billion in 2018.
“Even in developed countries, although we have seen significant reductions in smoking rates over recent decades, these reductions do seem in many cases to be stalling. And there is a significant group of smokers in both developed and developing countries who are unable or unwilling to quit using current approaches which is often quite ineffective in actually helping people to quit,” Dougan said.
The use of NNTPs, according to Dougan, is often seen as an appropriate intervention for helping them to stop smoking. “The use of NNTPs is based on the principle of harm reduction, specifically tobacco harm reduction.” he said.
